High-performance liquid chromatographic determination of seratrodast and its metabolites in human serum and urine.
A high-performance liquid chromatographic (HPLC) method was developed for the simultaneous determination of seratrodast, a new antiasthmatic drug, and its metabolites (M-I to M-III) in human serum and urine. The method for serum and urine with and without enzymatic hydrolysis using beta-glucuronidase involved liquid-liquid extraction and chemical oxidation with iron(III) chloride. The compounds in the extract were analyzed using HPLC with UV detection at 266 nm. The detection limits of seratrodast, M-I, M-II and M-III in serum and urine were 5-10 and 5-20 ng/ml, respectively, and those of deconjugated compounds in urine were 10-50 ng/ml. The method was applicable for human serum and urine from clinical trials.